Pacira Q1 revenue $168.9M, net income $4.8M; EXPAREL exclusivity extended to 2039

Pacira BioSciences, Inc.

2025-Q1 EPS reported $0.10 revenue$168,923,000

Total revenues $168.9M (+1% YoY); GAAP net income $4.8M ($0.10) vs $9.0M ($0.19) a year ago.
EXPAREL net sales $136.5M (+3% YoY) with 7% daily volume growth; ZILRETTA $23.3M (-10%).
Patent litigation settled with Fresenius Kabi; limited-volume entry starts at high single-digit % of U.S. volume, exclusivity to 2039.
Court ruling eliminates EXPAREL royalty obligation to RDF; future payments stopped, repayment sought.
Reiterates FY2025 guidance: revenue $725-765M, non-GAAP gross margin 76-78%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.